A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

Stopped early · Phase 2

Conditions studied: Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Brain Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Salivary Gland Neoplasms, Head and Neck Neoplasms, Thyroid Cancer, Papillary, Lymphoma, Large-Cell, Anaplastic, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Central Nervous System

In brief

This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.

Key facts

Study ID

NCT04644315

Run by

Hoffmann-La Roche

People needed

1

Starts

2021-05-24

Expected to finish

2022-05-16

Last updated by the study team

2023-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed ALK-positive locally-advanced or metastatic solid tumor excluding lung cancer
• ALK-positive tumor as per Foundation Medicine, Inc (FMI) next-generation sequencing (NGS) (NGS F1CDx, F1LCDx, or F1HEME) or per local accredited laboratory using validated NGS testing of tumor tissue or peripheral blood
• No alternative effective standard therapy available, or standard therapy considered unsuitable or intolerable to the participant
• Other cancer therapies are allowed, including investigational drugs, if any treatment-related toxicities (excluding alopecia) have resolved to grade </= 1 or to laboratory values as defined by the protocol
• Measurable disease at baseline as assessed by the Investigator per RECIST v1.1 or RANO criteria (for participants with primary CNS tumors)
• Life expectancy of at least 12 weeks
• Eastern cooperative oncology group (ECOG) performance status of 0-2
• Adequate hemataologic, hepatic, and renal function
• Participants with primary central nervous system (CNS) tumors are available
• Participants with brain or leptomeningeal metastasis are allowed in the study if asymptomatic and if they meet additional criteria as defined by the protocol
• Willingness to comply with study procedures
• Willingness to comply with home-base approach and visits by Mobile Nurses
• Ability to swallow alectinib capsules intact
• Women of childbearing potential must test negative for pregnancy at screening and prior to the first dose of study drug
• Women of childbearing potential must agree to remain abstinent or use contraceptive methods as defined by the protocol and refrain from donating eggs during the treatment period and for at least 90 days after the last dose of alectinib
• Men must agree to remain abstinent or use contraceptive methods as defined by the protocol and refrain from donating sperm during the treatment period and for at least 90 days after the last dose of alectinib

You may not qualify if…

• Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of alectinib
• Lung Cancer
• Patients with one of the following ALK point mutations: I1171X, G1202R, V1180L
• Prior therapy with an ALK inhibitor
• Liver disease as described in the protocol
• Known HIV, hepatitis B, or hepatitis C (HCV) infection
• Patients with symptomatic bradycardia
• Patients with symptomatic or unstable brain metastasis; patients with primary CNS tumors are allowed
• Malabsorption syndrome or any other condition that would interfere with enteral absorption
• Incomplete recovery from any surgery prior to treatment
• Any other malignancies within 5 years prior to enrollment, except for those described in the protocol
• Any serious medical condition or abnormality in clinical laboratory tests that, in the Investigator's judgment, precludes the patient's safe participation in and completion of the study
• History of hypersensitivity to any of the ingredients in the alectinib drug formulation

Where it is running

• Science 37, Inc — Culver City, California, United States
• Science 37-Basem; Dept 004- Basem — Culver City, California, United States
• Science 37-Beg; Dept 001 Dr. M. Beg — Culver City, California, United States
• Science 37-Cannon; Dept 002-Cannon — Culver City, California, United States
• Science 37-Kurzrock; Dept 005-Kurzrock — Culver City, California, United States
• Science 37-Thomas; Dept 006-Thomas — Culver City, California, United States
• Homebased Telemedicine — Los Angeles, California, United States
• Homebased Telemedicine — Sacramento, California, United States
• Homebased Telemedicine — San Diego, California, United States
• Homebased Telemedicine — San Francisco, California, United States
• Homebased Telemedicine — San Jose, California, United States
• Homebased Telemedicine — Jacksonville, Florida, United States
• Homebased Telemedicine — Miami, Florida, United States
• Homebased Telemedicine — Orlando, Florida, United States
• Homebased Telemedicine — Tampa, Florida, United States
• Homebased Telemedicine — Fort Wayne, Indiana, United States
• Homebased Telemedicine — Indianapolis, Indiana, United States
• Homebased Telemedicine — Minneapolis, Minnesota, United States
• Homebased Telemedicine — Saint Paul, Minnesota, United States
• Homebased Telemedicine — St Louis, Missouri, United States
• Homebased Telemedicine — Buffalo, New York, United States
• Homebased Telemedicine — New York, New York, United States
• Homebased Telemedicine — Philadelphia, Pennsylvania, United States
• Homebased Telemedicine — Pittsburgh, Pennsylvania, United States
• Homebased Telemedicine — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.